Drug Profile
Research programme: DNA repair enzyme inhibitors - KuDOS
Alternative Names: 1,3-dipropyl-7-methylxanthine; DNA repair enzyme inhibitors research programme - KuDOS; DPMX; KU 55933; KU-0060648; KU-0063794Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator KuDOS Pharmaceuticals
- Developer Galapagos NV; KuDOS Pharmaceuticals
- Class Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; DNA repair enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in United Kingdom
- 06 Apr 2011 Pharmacodynamics data from preclinical trials in Cancer presented at the 102nd Annual Meeting of the American Association for Cancer Research (AACR-2011)
- 19 Nov 2009 Pharmacodynamics data from in vitro & preclinical trials in Cancer presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)